Zacks Investment Research cut shares of CSPC Pharmaceutical Group Ltd (NASDAQ:CHPTY) from a buy rating to a hold rating in a report published on Tuesday.
According to Zacks, “CSPC Pharmaceutical Group Limited operates as a pharmaceutical group in China. Its bulk drug products include vitamin C, penicillin G and 7-ACA. The Company is also a major manufacturer of antibiotic finished drugs such as penicillin and cephalosporin products. CSPC Pharmaceutical Group Limited, formerly known as China Pharmaceutical Group Limited, is based in Wan Chai, Hong Kong. “
CSPC Pharmaceutical Group (NASDAQ:CHPTY) remained flat at $73.27 during mid-day trading on Tuesday. The company’s 50 day moving average price is $73.27 and its 200-day moving average price is $66.46. The company has a market cap of $8.87 billion and a P/E ratio of 31.18. CSPC Pharmaceutical Group has a one year low of $46.48 and a one year high of $73.36.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://weekherald.com/2017/08/12/cspc-pharmaceutical-group-ltd-chpty-downgraded-by-zacks-investment-research.html.
CSPC Pharmaceutical Group Company Profile
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CSPC Pharmaceutical Group Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSPC Pharmaceutical Group Ltd and related companies with MarketBeat.com's FREE daily email newsletter.